MIMichinori Ishitoku

Michinori Ishitoku

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michinori Ishitoku has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Perspectives of rheumatologists on the management of late-onset rheumatoid arthritis: a nationwide cross-sectional survey

    by Satoshi Takanashi, Yuko Kaneko, Yutaka Kawahito, Takashi Kida, Takahiko Sugihara, Toshihisa Kojima, Ryozo Harada, Michinori Ishitoku, Shintaro Hirata, Motomu Hashimoto, et al.

  • Persistent parvovirus B19 infection in an older patient with rheumatoid arthritis receiving immunosuppressive therapy: A case report and literature review

    by Masako Oyama, Yusuke Yoshida, Tetsumi Yoshida, Hiroki Kobayashi, Yuji Shigemasa, Hirohisa Usagawa, Makoto Fujii, Michinori Ishitoku, Tomohiro Sugimoto, Shintaro Hirata

    An 84-year-old man with rheumatoid arthritis undergoing treatment with methotrexate presented with fever, general fatigue, and appetite loss. He had a 3-month history of unexplained normocytic anaemia with reticulocytopenia. Bone marrow examination revealed erythroid hypoplasia with giant pro-erythroblasts, leading to a diagnosis of parvovirus B19 infection. In this case, intravenous immunoglobulin therapy improved the patient’s anaemia and systemic symptoms. Six months after the treatment, parvovirus B19 DNA remained detectable using polymerase chain reaction; however, the viral load had markedly decreased, indicating a favourable virological response. Twenty cases of parvovirus B19 infection in older adults (aged ≥65 years) were identified in the literature. Immunocompromised older patients frequently develop persistent parvovirus B19 infections that require treatment with intravenous immunoglobulin therapy, whereas persistent infections are not observed in immunocompetent older individuals. Therefore, this case suggests that clinicians should be aware of persistent parvovirus B19 infection in older immunosuppressed patients who develop unexplained anaemia with reticulocytopenia. Moreover, intravenous immunoglobulin therapy may be considered as an effective therapeutic option for persistent parvovirus B19 infection in immunocompromised patients.

  • Open Access

    Mepolizumab add-on after relapse during rituximab maintenance in MPO-ANCA-positive eosinophilic granulomatosis with polyangiitis: a case report and literature review

    by Genki Kidoguchi, Michinori Ishitoku, Tomohiro Sugimoto, Yusuke Yoshida, Shintaro Hirata

    Eosinophilic granulomatosis with polyangiitis is a heterogeneous vasculitic and eosinophilic disorder in which patients who are positive for myeloperoxidase antineutrophil cytoplasmic antibody often develop glomerulonephritis and peripheral neuropathy and may require prolonged immunosuppressive therapy. Although rituximab and mepolizumab have been used in selected patients with EGPA, relapse during rituximab maintenance remains difficult to manage. We report a 59-year-old woman with adult-onset asthma and chronic rhinosinusitis who presented with severe eosinophilia, mononeuritis multiplex, myeloperoxidase anti-neutrophil cytoplasmic antibody positivity, and pauci-immune necrotising glomerulonephritis. Induction therapy with high-dose glucocorticoids, intravenous immunoglobulin, and rituximab achieved clinical remission and allowed tapering to a low dose of prednisolone. Despite rituximab maintenance, she later relapsed with recurrent sinonasal symptoms, worsening neuropathic complaints, and a marked rise in myeloperoxidase antineutrophil cytoplasmic antibody levels. In this setting, further escalation of immunosuppression during maintenance, including cyclophosphamide, may be considered; however, given the possibility that residual eosinophilic inflammation contributed to ongoing disease activity, including autoantibody production, mepolizumab was added after retreatment with rituximab as sequential therapy. Symptoms stabilised and improved over subsequent months, myeloperoxidase antineutrophil cytoplasmic antibody titres progressively declined to the normal range, and prednisolone was discontinued. Remission has been maintained on mepolizumab without further rituximab for maintenance. This case suggests that sequential eosinophil-targeted therapy may help consolidate remission after relapse during rituximab maintenance in myeloperoxidase antineutrophil cytoplasmic antibody–positive eosinophilic granulomatosis with polyangiitis.

  • Open Access

    Effect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial

    by Yusuke Yoshida, Yohei Hosokawa, Takanori Taogoshi, Naoya Oka, Hiroki Kobayashi, Genki Kidoguchi, Kei Araki, Michinori Ishitoku, Tomohiro Sugimoto, Sho Mokuda, et al.

    Introduction: Folic acid is routinely co-administered with methotrexate (MTX) to reduce toxicity; however, the optimal dose remains unclear. This study investigated whether increasing the weekly folic acid dose from 5 to 10 mg reduces MTX-related toxicity in patients receiving stable-dose MTX therapy. Methods: In this single-center, open-label, randomized controlled trial, 44 patients with rheumatic diseases on stable-dose MTX either received 10 mg (ARM-1) or 5 mg (ARM-2) of folic acid per week for 12 weeks. Liver damage, other MTX-related toxicities, and erythrocyte MTX-polyglutamate (MTX-PG) concentrations were compared between groups using logistic regression analysis or analysis of covariance. Japan Registry of Clinical Trials (number: jRCT1061230085). Results: Forty-two patients completed the study. The presence of liver damage at Day 84 did not differ significantly between the two groups (OR 0.41, 95% CI, 0.01–5.75, p = 0.506). Adjusted mean differences in aspartate transaminase and alanine transaminase at Day 84 between the groups were − 0.33 U/L (95% CI, − 2.68 to 2.02; p = 0.779) and − 0.44 U/L (95% CI, − 5.39 to 4.51; p = 0.859). Comparison of outcomes between groups at Day 84 showed no significant differences in any outcomes, except for fatigue severity (adjusted mean difference, − 0.87; 95% CI, − 1.71 to − 0.04; p = 0.041). Baseline fatigue was associated with baseline MTX-PG2 or MTX-PG1-2 concentrations (OR, 1.06; p = 0.049 or OR, 1.03; p = 0.040, respectively). Conclusions: Increasing folic acid dose to 10 mg/week showed little effect on reducing MTX-related toxicity, although it may improve fatigue in selected patients. Key Points • Increasing the weekly folic acid dose from 5 mg to 10 mg showed no additional benefit in reducing methotrexate-related toxicity in patients on stable-dose MTX. • Higher-dose folic acid was associated with improved fatigue severity, indicating a potential therapeutic option for patients who develop fatigue.

  • Open Access

    Serum calprotectin elevation and interferon-α-induced neutrophil priming in macrophage activation syndrome associated with systemic lupus erythematosus: Clinical and experimental insights

    by Yohei Hosokawa, Yusuke Yoshida, Sho Mokuda, Naoya Oka, Hiroki Kobayashi, Genki Kidoguchi, Michinori Ishitoku, Tomohiro Sugimoto, Shintaro Hirata

    Objectives: To clarify the diagnostic utility of serum calprotectin and gene expression in interferon (IFN)-α-activated neutrophils in macrophage activation syndrome (MAS) in patients with systemic lupus erythematosus (SLE). Methods: This single-centre, cross-sectional study analysed serum calprotectin levels in 47 patients with SLE (including eight with MAS) and 7 patients with adult-onset Still’s disease (AOSD) complicated with MAS as a reference population. In neutrophil-based experiments, mRNA expression levels of S100A8 and S100A9 were measured following stimulation with IFN-α or interleukin (IL)-1β. Results: Serum calprotectin levels were significantly elevated in patients with SLE-MAS compared to those with SLE without MAS and comparable to those in patients with AOSD-MAS. Calprotectin levels correlated with serum ferritin levels (rs = 0.49, P = .004), but not with anti-dsDNA antibodies or complement levels. At a cut-off value of 9184.4 ng/ml, serum calprotectin demonstrated sensitivity of 62.5% and specificity of 94.9% for identifying MAS. Recombinant IFN-α2a induced a dose-dependent increase in S100A8 and S100A9 expression in neutrophils, whereas recombinant interleukin-1β had no effect. Pre-treatment with an anti-IFN-α2 neutralising antibody effectively suppressed the IFN-α2a-induced expression of S100A8 and S100A9. Conclusions: Serum calprotectin, upregulated by IFN-α, may serve as a useful biomarker for diagnosing MAS in SLE.

  • Open Access

    Tumor Necrosis Factor and Interleukin-1β Upregulate NRP2 Expression and Promote SARS-CoV-2 Proliferation

    by Michinori Ishitoku, Sho Mokuda, Kei Araki, Hirofumi Watanabe, Hiroki Kohno, Tomohiro Sugimoto, Yusuke Yoshida, Takemasa Sakaguchi, Junya Masumoto, Shintaro Hirata, et al.

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), utilizes the host receptor angiotensin-converting enzyme 2 (ACE2) and the auxiliary receptor Neuropilin-1 (NRP1) to enter host cells. NRP1 has another isoform, NRP2, whose function in COVID-19 has seldom been reported. In addition, although patients with severe cases of COVID-19 often exhibit increased levels of proinflammatory cytokines, the relationship between these cytokines and SARS-CoV-2 proliferation remains unknown. The aim of this study is to clarify the roles of proinflammatory cytokines in Neuropilin expressions and in SARS-CoV-2 infection. To identify the expression patterns of NRP under inflamed and noninflamed conditions, next-generation sequencing (RNA-seq), immunohistochemistry, quantitative real-time PCR, and Western blotting were performed using primary cultured fibroblast-like synoviocytes, MH7A (immortalized cell line of human rheumatoid fibroblast-like synoviocytes), immortalized MRC5 (human embryonic lung fibroblast), and synovial tissues. To measure viral proliferative capacity, SARS-CoV-2 infection experiments were also performed. NRP2 was upregulated in inflamed tissues. Cytokine-stimulated human fibroblast cell lines, such as MH7A and immortalized MRC5, revealed that NRP2 expression increased with co-stimulation of tumor necrosis factor α (TNFα) and interleukin-1 beta (IL-1β) and was suppressed with anti-TNFα antibody alone. TNFα and IL-1β promoted SARS-CoV-2 proliferation and Spike protein binding. The viral proliferation coincided with the expression of NRP2, which was modulated through plasmid transfections. Our results revealed that proinflammatory cytokines, including TNFα, contribute to NRP2 upregulation and SARS-CoV-2 proliferation in host human cells.


  • N1-methylpseudouridine-incorporated mRNA enhances exogenous protein expression and suppresses immunogenicity in primary human fibroblast-like synoviocytes

    by Sho Mokuda, Hirofumi Watanabe, Hiroki Kohno, Michinori Ishitoku, Kei Araki, Shintaro Hirata, Eiji Sugiyama

    Studies conducted using murine arthritis models have indicated that the use of in vitro-transcribed messenger RNA (IVT mRNA) is an effective therapeutic approach for joint diseases. However, the use of IVT mRNA in human synovial cells has not been widely studied. Recently, the outbreak of the novel coronavirus disease has accelerated the development of innovative mRNA vaccines, such as those containing a modified nucleic acid, N1-methylpseudouridine-5′-triphosphate (m1ψ). IVT mRNA is an attractive tool for biological experiments and drug discovery. To verify the protein expression from IVT mRNA in vitro, primary cultured fibroblast-like synoviocytes (FLS) and MH7A human synovial fibroblast cells were transfected with enhanced green fluorescent protein (EGFP) mRNA with or without m1ψ incorporation. EGFP was detected using western blotting and fluorescence microscopy. A multiplex assay was performed to comprehensively understand IVT mRNA-induced immunogenicity. Gene expression levels were measured using reverse transcription polymerase chain reaction. In both MH7A cells and FLS, cells transfected with EGFP mRNA containing m1ψ generated higher levels of EGFP than those transfected with unmodified EGFP or control mRNAs. The multiplex assay of the FLS culture supernatant and reverse transcription polymerase chain reaction for FLS revealed that both concentration and expression of IL-6, TNF-α, and CXCL10 were upregulated by unmodified EGFP mRNA, whereas they were suppressed by EGFP mRNA with m1ψ. Overall, m1ψ incorporation enhanced protein expression and decreased the expression of cytokines. These findings may contribute to arthritis research.